Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Juventas
company
About
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- ¥410M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥410M
Juventas has raised a total of
¥410M
in funding over 2 rounds. Their latest funding was raised on
Jul 12, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 12, 2021 | Series C | ¥410M | 4 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
4
Juventas is funded by 4 investors.
Haisong Capital
and Tianchuang Zhixing (Beijing) Touzi Guanli Zixun Youxian Gongsi
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series C |
|
|
— | Series C |
|
|
— | Series C |
Ding Xiang Capital
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
